Connect with us

Technology

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

Published

on

NANJING, China, Sept. 2, 2024 /PRNewswire/ — On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx Inc. The partnership focuses on the ALK/ROS1 dual receptor tyrosine kinase inhibitor TGRX-326, a clinical-stage anti-tumor candidate.

According to the terms of the agreement, Simcere Zaiming will acquire exclusive commercial rights to TGRX-326 in Mainland China. These rights encompass but are not limited to marketing promotion, strategy formulation and adjustment, and the right to obtain relevant benefits from TGRX-326. TargetRx will receive an initial payment exceeding $20 million. Additionally, TargetRx will compensate Simcere Zaiming for promotional services.

TGRX-326 is a third-generation anaplastic lymphoma kinase (ALK) inhibitor independently developed by TargetRx. It is a potent and highly selective small molecule inhibitor that targets ALK and c-ROS proto-oncogene 1 (ROS1) receptor tyrosine kinases (RTKs). This inhibitor holds significant therapeutic potential for ALK/ROS1 fusion gene-positive non-small cell lung cancer (NSCLC) patients, especially those with multiple ALK-resistant mutations, including G1202R.

In preclinical studies and a Phase 1 clinical trial, TGRX-326 demonstrated robust anti-tumor activity and a favorable safety profile. Moreover, the molecule effectively crosses the blood-brain barrier, exhibiting exceptional efficacy in NSCLC patients with brain metastases.

Dr. Renhong Tang, Chairman of Simcere Zaiming, said, “We are pleased to collaborate with TargetRx on novel dual-targeted therapy for lung cancer, a major malignancy that Simcere Zaiming strategically focuses on. This partnership will further enhance our innovative product portfolio. ALK/ROS1 fusion is a critical genetic mutation in non-small cell lung cancer. The advancement of targeted therapies has significantly improved survival rates for these patients. However, there remains a substantial need for new treatments with better efficacy and the ability to overcome drug resistance. We look forward to working closely with TargetRx to provide Chinese lung cancer patients with more effective treatment options as soon as possible.”

Dr. Yihan Wang, Chairman of TargetRx, said, “TGRX-326 is a potentially best-in-class novel anti-tumor molecule independently developed by TargetRx. It is a third-generation ALK inhibitor in late-stage clinical development which may bring a better option for patients. We believe that with the support of Simcere Zaiming, we will be able to bring this product quickly to the market. TargetRx aims to continuously deliver innovative therapies that will transform the lives of cancer patients.”

About Simcere Zaiming

Simcere Zaiming, an oncology-centric biopharmaceutical subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096), was established in 2023. The company is dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several products in China, including COSELA®, Endostar®, Enweida®, and Enlituo®. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners in cancer therapeutics. 

About TargetRx

TargetRx is a clinical stage, high-tech pharmaceutical R&D company focused on developing next-generation targeted therapies for cancer patients, particularly those who are resistant or refractory to current treatments. TargetRx has developed a series of cutting-edge and efficient small molecule drug discovery platforms, which combine innovative research and development capabilities for drug design, screening, evaluation and optimization. Since its establishment, TargetRx has been granted over 170 patents from authorities in China, the US, Europe, Japan and other regions. Several potential best-in-class compounds are at different stages of multi-national clinical trials.

View original content:https://www.prnewswire.com/news-releases/simcere-zaiming-collaborates-with-targetrx-to-introduce-a-third-generation-alk-inhibitor-302235944.html

SOURCE Simcere Pharmaceutical Group Limited

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Lojas Renner Announces First Quarter 2025 Earnings Results

Published

on

By

PORTO ALEGRE, Brazil, May 8, 2025 /PRNewswire/ — Lojas Renner S.A. (B3: LREN3), announces its results for the first quarter 2025 (1Q25). All amounts are expressed in millions of Reais and all comparisons are with the same period for the previous year, except when otherwise indicated.

Highlights

Apparel sales increased 13.5%Gross margin increased 0.6p.p., with the lowest level of markdowns in 1s0 years and +5.4p.p. in CamicadoYoucom sales increased by 28%Fifth consecutive quarter of expenses dilution, at 1.3p.p.Realize with result of R$ 191 MM (~R$ 95 MM on a comparable basis ex Central Bank resolution) and a significant improvement in portfolio riskTotal Adjusted EBITDA reached R$ 585 MM (+55%) with margin of 21.2% (+5.8p.p.)Cash position of R$ 1.6 bi and net cash of R$ 1.2 bi62% of the buyback program executed (46,5 million shares repurchased) until nowNet profit of R$ 221 million (+59%) and Earnings Per Share up by 65%1.9 p.p. increase in ROIC (ROIC LTM of 13.3%)

Message from the CEO
Lojas Renner’s first-quarter results demonstrate that the evolution of our business model and the initiatives we have implemented are gradually bearing fruit while enhancing our competitiveness.

First quarter apparel sales increased by 13.5% while consolidated gross margin increased by 0.6 p.p., also with the lowest level of markdowns in the last 10 years. We delivered operating leverage for the fifth consecutive quarter – which improved by 1.3 p.p. in 1Q25- and achieved R$ 221 million (+59%) in net profit, resulting in a 1.9 p.p. increase in ROICLTM, which reached 13.3% for 1Q25.

Part of this performance for the quarter reflects the sustained, gradual effects of Renner’s more agile and flexible fashion execution, combined with an increasingly precise supply model (100% by SKU) and shorter lead times for stores. Additionally, the increasingly differentiated and integrated shopping journey across all of Renner’s businesses contributed to the improvement in NPS and an increase in the active customer base during the quarter. Digitalization of the shopping experience continued to evolve at Renner stores, and Digital GMV gained even more relevance, increasing by 15% with 16% penetration and higher profitability.

Realize delivered its sixth consecutive quarter of improved operational results, also benefiting from adjustments related to the new Bacen resolution. However, excluding the Bacen effect, Realize results improved significantly (+7 times). Credit portfolio quality continued to evolve during the quarter, and this business continued to drive Renner’s retail operations as an important catalyst to customer loyalty and value generation.

It’s important to also note the strong performance at Youcom and Camicado, with a 28% increase in Youcom sales and a 5.4 p.p. increase in Camicado’s gross margin for 1Q25.

While we’re pleased with Renner’s first quarter performance as a positive start to the year, our evolution will be more challenging given our high nominal base. However, our progress related to key metrics this quarter demonstrates that we are on the right track. Further, our Company’s solid cash position of R$ 1.6 billion enables us to make strategic investments aimed at growth and to capture opportunities in the current environment. Similarly, our strong balance sheet provided us the flexibility during the quarter to execute 62% of the share buyback program we announced in February, with 46.5 million shares repurchased to date. Our potential is greater. And while there remains considerable opportunity for further evolution on this journey, our investments were made to achieve this objective. We remain focused on our priority of accelerating our ability to capture our evolved business model’s full potential, and we reaffirm our commitment to sustained long-term growth, with profitability, and value generation.
Fabio Faccio – CEO

For a full version of Lojas Renner’s Results, please visit: https://lojasrenner.mzweb.com.br/en/

Earnings Conference Call*
Date: May 9, 2025
Time: 10:00 AM BRT / 9:00 AM ET
*Portuguese with a simultaneous English translation.
Access the webcast here.

About Lojas Renner S.A.
The Company was incorporated in 1965 and listed in 1967, becoming a pure widely held company in 2005 with a 100% free float, being considered the first true Brazilian corporation. Renner’s equities are traded on B3 under the LREN3 symbol in the Novo Mercado segment, the highest level of corporate governance

Lojas Renner S.A. is a fashion and lifestyle ecosystem connected to its customers through digital channels and its physical stores in Brazil, Argentina and Uruguay. It is today the ecosystem leader in omnichannel fashion retailing in Brazil through the Renner, Camicado, Youcom, Realize CFI and Repassa businesses.

Legal Notice
The statements contained in this document relate to the prospects for the business, estimates for operating and financial results and those related to growth prospects of Lojas Renner S.A. are merely projections and, as such, are based exclusively on the expectations of the Company’s management with respect to the future of the business. Such forward-looking statements depend substantially on changes in market conditions, the performance of the Brazilian economy, the sector and the international markets and are therefore subject to change without prior notice.

View original content:https://www.prnewswire.com/news-releases/lojas-renner-announces-first-quarter-2025-earnings-results-302450652.html

SOURCE Lojas Renner S.A.

Continue Reading

Technology

Quebecor Inc. announces election of directors

Published

on

By

MONTRÉAL, May 8, 2025 /CNW/ – In accordance with the TSX Company Manual, Quebecor Inc. (TSX: QBR.A) (TSX: QBR.B) is issuing this news release to disclose the voting results for the election of directors held at its Annual Meeting of Shareholders held today.

All of the proposed nominees were duly elected as directors of the Corporation by the shareholders present or represented by proxy at the meeting. The results of the vote were as follows:

CLASS “A” DIRECTORS *  

VOTES FOR 

%

VOTES 
WITHHELD  

%

André P. Brosseau

73,631,551

99.99

3,323

0.01

Michèle Colpron

73,627,285

99.98

7,589

0.02

Lise Croteau

73,628,481

99.99

6,393

0.01

Sylvie Lalande

73,627,681

99.99

7,193

0.01

Érik Péladeau

73,631,694

99.99

3,180

0.01

Jean B. Péladeau

73,628,224

99.99

6,650

0.01

CLASS “B” DIRECTORS **  

VOTES FOR 

%

VOTES 
WITHHELD 

%

Chantal Bélanger

119,809,865

98.26

2,123,655

1.74

Frantz Saintellemy

121,142,665

99.35

790,855

0.65

* Elected by the Class “A” shareholders
** Elected by the Class “B” shareholders

About Quebecor

Quebecor, a Canadian leader in telecommunications, entertainment, news media and culture, is one of the best-performing integrated communications companies in the industry. Driven by their determination to deliver the best possible customer experience, all of Quebecor’s subsidiaries and brands are differentiated by their high-quality, multiplatform, convergent products and services.

Québec-based Quebecor (TSX: QBR.A, QBR.B) employs more than 11,000 people in Canada.

A family business founded in 1950, Quebecor is strongly committed to the community. Every year, it actively supports more than 400 organizations in the vital fields of culture, health, education, the environment and entrepreneurship. 

Visit our website: www.quebecor.com 

SOURCE Québecor

Continue Reading

Technology

Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB

Published

on

By

PALM BEACH, Fla., May 8, 2025 /PRNewswire/ — Exec Edge announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates.

Exec Edge Research is a highly specialized platform focused on US and global equities, with an emphasis on fundamental analysis. Our first round of initiation reports includes Fold Holdings, Inc (Nasdaq: FLD), Climb Bio Inc. (Nasdaq: CLYM), Rex American Resources Corp. (NYSE: REX), The ONE Group Hospitality, Inc. (Nasdaq: STKS) and Aurora Cannabis Inc. (Nasdaq: ACB).

Our reports dive deep into industry data, publicly-disclosed company financials, management teams, and valuation. Exec Edge Editorial handpicks our coverage universe and we aim to explain investment highlights and risks but will not issue price targets or trading recommendations. All reports are available at executives-edge.com/category/research/ and can be found under company tickers via our content partners, Yahoo! Finance and Bloomberg Terminals.

“We are launching Exec Edge Research to provide an additional tool for retail investors, family offices and other investors who likely do not get access to sell-side research, but value detailed company insights and summaries from earnings and events,” said John Jannarone, CEO of Capital Markets Media LLC, parent of Exec Edge Research. “Our goal is to highlight some of these companies when we conduct interviews and media events at the NYSE and Nasdaq.”

Overview of First 5 Initiation Notes

With our first report we tapped into the burgeoning Bitcoin (BTC) economy with Fold Holdings, Inc. (NASDAQ: FLD), the first publicly-traded financial services company that combines Bitcoin ownership with business lines tied to the increasing popularity of the cryptocurrency. Fold attracts customers with a unique positioning between traditional banking services and the digital asset economy and equity investors by offering attractively priced exposure to the BTC market – but also an unusual hedge against crypto‘s notorious volatility. READ THE FULL REPORT HERE.As one of the brightest emerging biotechnology companies, Climb Bio Inc. (NASDAQ: CLYM) aims to improve the efficacy of autoimmune disease treatment. With its recently-acquired lead asset, Budoprutug, and exclusively licensed Anti-APRIL antibody, CLYM116, the innovative biotech play is positioned to pull ahead of the pack. As the company moves through more successful development stages, more investors are likely to take notice. READ THE FULL REPORT HERE.It’s time investors consider harvesting a new generation of profits from the vast American Corn Belt with Rex American Resources Corp. (NYSE: REX). The leading ethanol manufacturer with a stronghold in the U.S. Midwest may soon reap the benefits of two major investment initiatives. With a fully cash-funded investment budget of $165$175 million, a fraction of cash on hand, a deliberate growth strategy is combined with financial prudence. With a conservative balance sheet, new growth efforts in motion and an attractive valuation, Rex remains — for now — an undiscovered play on renewable energy. READ THE FULL REPORT HERE.How about steak and a show for dinner and best-in-class growth for dessert? Investors can enjoy just that with The ONE Group Hospitality, Inc. (Nasdaq: STKS). The operator of 167 full-service experience-driven dining establishments recently acquired Safflower Holdings, parent of world-famous Benihana (known for hibachi-side chef performances) and RA Sushi. For the moment, STKS shares are on sale, trading at a debt-adjusted EV of just 5.2 times forward EBITDA, less than half the multiple commanded by Brinker International, Inc. and The Cheesecake Factory Inc. READ THE FULL REPORT HERE.Aurora Cannabis Inc. (Nasdaq: ACB), a federally-licensed producer of medical and consumer cannabis, is attractively positioned as an early leader in global regulated markets. ACB leverages a best-in-class brand portfolio to grow and sell products across all major cannabis categories. And it’s translating to results: the company just delivered a top-down beat on strengthening industry tailwinds and expanding global sales. READ THE FULL REPORT HERE.

Looking ahead, readers can anticipate two initiation notes each month and a timely analysis of quarterly reports for all covered companies. Readers can subscribe to our mailing list for regular updates at executives-edge.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/exec-edge-launches-research-coverage-with-initiation-notes-on-fld-clym-stks-rex-acb-302450536.html

SOURCE CorpGov

Continue Reading

Trending